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Abstract
The presence of a ‘low T3 syndrome’ in the setting of nonthyroidal
illness has long been recognized as the ‘euthyroid sick syndrome’,
with the recommendation to observe and not treat with thyroid
hormone replacement therapy. That approach has recently been
challenged in the setting of critical cardiac illness. Research
demonstrating that thyroid hormone therapy may improve
hemodynamic parameters has rekindled interest in the use of
thyroid hormone therapy in critical illness. Continued improvements
in survival after critical cardiac illness provokes the question of
whether thyroid hormone therapy would provide further incremental
benefit.
The question of whether thyroid hormone supplementation
should be provided to critically ill patients without a known
history of thyroid disease is not a new debate [1]. Analysis of
such patients led to the recognition of the euthyroid sick
syndrome, which is characterized by low normal thyroxine (T4)
levels, low normal 3,5,3′-tri-iodothyronine (T3) levels, variable
thyroid-stimulating hormone (TSH) levels and elevated
3,3′,5′-tri-iodothyronine (reverse T3; rT3) levels. The physio-
logic changes that lead to these alterations are the body’s
attempt to conserve metabolism during illness. T4 is normally
metabolized through sequential deiodination to T3 then to
3,3′-di-iodothyronine (T2), which is then rapidly degraded to
monoiodothyronines and thyronine [2]. Normally, about 40%
of secreted T4 is monodeiodinated in the 5′ position to yield
T3, and a similar fraction is monodeiodinated in the 5 position
to yield rT3. The body responds to illness by shunting T4
disproportionately towards rT3, which cannot be converted to
the biologically active form of T3 but only deiodinated to T2.
Although this process makes sense teleologically as a form of
conservation of energy, these authors raise the question of
whether this could actually impair the body’s response to the
acute illness, namely the myocardial ischemia [3].
Unfortunately, they initially try to create an argument that the
acute episode was associated with relative hypotension to
the hypothalamic–pituitary axis leading to a ‘low T3
syndrome’, although they are not able to offer any proof that
such ischemia occurs in their cohort. They do mention the
more likely etiology, which is cytokine-mediated suppression
of T3 production. Cytokines, including IL-6, IL-1, and tumor
necrosis factor-α, contribute to the suppression of the 5′
deiodinase, thus shunting T4 into rT3 [4]. Cytokines can also
contribute to the suppression of TSH. This raises an
interesting question of whether the level of TSH, either in
itself or in how it changes over the illness, has any prognostic
information. Critically ill patients with the euthyroid sick
syndrome can have a very low TSH level or it can be as high
as 20 µIU/ml [5]. It is very possible that the higher TSH level
represents recovery manifested as an asynchronous return of
the hypothalamic–pituitary and thyroid axes to normal. Thus,
as they recover from the acute illness they seem, transiently, to
have a form of primary hypothyroidism. Because one does not
know what phase of recovery a patient has reached, we have
focused on maintaining the T4, which is the ‘storage form’ of
the hormone, in the normal range.
This study of patients with acute cardiac illness is of interest
because the authors are proposing that as we are able to
resuscitate many of these acutely ill patients they will then
have increased T4 requirements, and the ‘low T3 syndrome’
might actually hinder our efforts. If this is a true ‘low T3
syndrome’ due to hypothalamic–pituitary ischemia,
combination T4/T3 therapy might be of value during the period
of decreased production. This could be differentiated from
the euthyroid sick syndrome by measuring reverse T3 levels. If
it were truly a simple deficit in T3 production, reverse T3
should also be low. If reverse T3 is high, then what these
authors are describing is truly the euthyroid sick syndrome.
Although the traditional approach is to not treat the euthyroid
sick syndrome with levothyroxine because it will all be
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shunted into rT3, the authors ask whether we should consider
treating cardiac patients who have the euthyroid sick
syndrome with T3 (and not T4) to facilitate cardiac recovery.
There is now evidence that the provision of T3 improves
hemodynamic parameters after open-heart surgery [6-8].
Studies in animals have shown that T3 administration after an
acute myocardial infarction is associated with a better left
ventricular ejection fraction, which is very thought-provoking
because left ventricular function is an important indicator of
outcome after an acute myocardial infarction [9]. Although
there will be resistance from the endocrinology community to
trials of T3 therapy in acutely ill patients, one must carefully
consider whether it might have utility in a specific subset of
patients – as these authors propose – who have an acute
myocardial event. For that reason, this issue might need to be
considered seriously in a prospective randomized trial.
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